RAPP
Rapport Therapeutics, Inc.$25.93 −0.60 (−2.26%)
Oct 23 4:00 PM ET · prev $26.53
SecBot read Bullish lean 8 reports, 90 days 1 bearish · 4 bullish· 3 neutral or mixed · weighted by impact and recency
- Strongest
- Rapport Therapeutics announced positive topline Phase 2 results for RAP-219… impact 7 · Oct 20
- Also
- A cluster of insider purchases at Rapport Therapeutics, Inc. (RAPP) shows… (Oct 23)·Two insiders at Rapport Therapeutics, including the CFO and a director, made… (Oct 22)
- Next catalyst
- Earnings date, Nov 5, 2026
Market cap
$1.3B
Small cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
🔒 Subscribers only
1 year
0.0%
from $25.93 · Oct 24
30 days
−23.4%
from $33.83
52-week range
$24.37–52.50
−51% from high · low Nov 14
Avg volume 20D
919.3K
Oct 20 spike 8.20M
Short interest
3.19M
≈6.7% of shares · +42.1%
Days to cover
4.8
at average volume
Insider net
-$24.4M
6 buyers · 4 sellers · since Apr 17
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
63°
Warm · 4 mentions this week
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, filings and short-interest jumps.
No data for this timeframe.
- R Apr 21 Rapport Therapeutics announced positive follow-up data from its Phas…
- E Apr 21 FDA: Rapport Therapeutics Presents RAP-219 Focal Onset Seizure…
- S Aug 10 to Aug 11 2 days of insider sells: $2.4M by 1 insider, avg $47.25
- S Aug 19 to Aug 25 3 days of insider sells: $3.5M by 2 insiders, avg $50.22
- S Sep 23 to Oct 7 4 days of insider sells: $561.7K by 2 insiders, avg $33.57
- X Sep 30 Short interest jumps 42.1% to 3.19M
- A Oct 15 2 analysts initiate
- B Oct 21 to Oct 23 3 days of insider buys: $1.7M by 6 insiders, avg $26.99
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders bought $1.7M at an average $26.99. 4 insiders sold $26.1M.
- InstitutionsBULLISH
Q2 2026: 19 added (0 new), 8 trimmed or exited.
- AnalystsBULLISH
18 of 19 rate it Buy or better.
- Short sellersBUILDING
Short interest +42.1% to 3.19M shares. 4.8 days to cover, ≈6.7% of shares.
- TrendDOWNTREND
34% below its 50-day average.
- SocialQUIET
Crowd 63° (warm) this week from 4 mentions: 2 bullish, 0 bearish. No setup call.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | $26.8M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $15.1M |
| Candriam S.C.A. | ADD | $14.5M |
| MORGAN STANLEY | ADD | $12.4M |
| MILLENNIUM MANAGEMENT LLC | TRIM | $6.5M |
| Nuveen, LLC | ADD | $4.3M |
| Walleye Capital LLC | DOUBLED | $4.3M |
| BANK OF AMERICA CORP /DE/ | TRIM | $3.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analysts 95% rate it Buy or better
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | Jones Trading MAINTAIN | Buy |
| Oct 21, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 21, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 20, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 20, 2026 | BTIG MAINTAIN | Buy |
| Oct 15, 2026 | UBS INITIATE | Buy |
Insider ledger
Form 4$1.7M
bought · 6 insiders
$26.1M
sold · 4 insiders
−3.9%
vs their $26.99 cost
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 23, 2026 | Sanchez Ramiro Director | BUY | $98.5K |
| Oct 22, 2026 | Young Wendy B. Director | BUY | $100.0K |
| Oct 22, 2026 | Silva Paul M Director | BUY | $99.6K |
| Oct 22, 2026 | MARAGANORE JOHN Director | BUY | $31.5K |
| Oct 22, 2026 | PAUL STEVEN M Director | BUY | $974.3K |
| Oct 22, 2026 | MARAGANORE JOHN Director | BUY | $217.3K |
| Oct 21, 2026 | Ceesay Abraham Chief Executive Officer | SELL | $64.4K |
| Oct 21, 2026 | Ignelzi Troy A. Chief Financial Officer | BUY | $143.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data — subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data — subscribers only | |||
| Next Q | 🔒 Fresh data — subscribers only | |||
| Current FY | 🔒 Fresh data — subscribers only | |||
| Next FY | 🔒 Fresh data — subscribers only | |||
Reddit mentions per day, 14 days
Crowd this week 63° Warm 2 bullish · 0 bearish
Mentions, 7 days 4 3 in posts · 1 in comments
Recent posts
Insider buying and selling this week
5 upvotes · 0 comments
Insider buying and selling this week
1 upvotes · 0 comments
⚡MORNING WATCHLIST⚡
3 upvotes · 2 comments
Recent comments
All social signals and their track recordsShort side
FINRA· Sep 30, 20263,194,008
shares short
+42.1%
vs prior settlement
4.8
days to cover
≈6.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
A cluster of insider purchases at Rapport Therapeutics, Inc. (RAPP) shows five directors and the CFO buying a total of…
CLUSTER — Impact 5/10
Oct 23, 2026 Insider
Oct 22, 2026 SEC Sanchez Ramiro bought 3,600 shares
Director @ $27.35 ($98.5K)
Two insiders at Rapport Therapeutics, including the CFO and a director, made open-market purchases totaling $361K over…
CLUSTER — Impact 5/10
Oct 22, 2026 Insider
Young Wendy B. bought 3,789 shares
Director @ $26.39 ($100.0K)
Oct 22, 2026 Insider
Oct 21, 2026 SEC Silva Paul M bought 3,680 shares
Director @ $27.08 ($99.6K)
Rapport Therapeutics CFO Troy Ignelzi purchased $144K worth of RAPP shares on the open market at $26.10 per share on…
INSIDER-BUY — Impact 4/10
Sep 30, 2026 Short interest report
Short Interest: RAPP up 42% to 3.2M shares
Settlement 2026-09-30 | Days to cover: 4.84 | ≈6.66% of shares outstanding (est.)
Jun 30, 2026 Inst.
UBS AM, a distinct — TRIM
644,082 shares ($26.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 30, 2026
Short interest
Short Interest: RAPP up 42% to 3.2M shares
Settlement 2026-09-30 | Days to cover: 4.84 | ≈6.66% of shares outstanding (est.)
Sep 2, 2026
Press release
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Aug 24, 2026
Press release
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Aug 6, 2026
Earnings date
RAPP Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings date
RAPP Q2 2026 Earnings Scheduled — 2026-08-05
Filing reports
19 analyzed · 4 bullish · 4 bearish · 2 mixed · 9 neutral· 3 press- BULLISHCLUSTEROct 23, 2026
A cluster of insider purchases at Rapport Therapeutics, Inc. (RAPP) shows five directors and the…
Impact 5/10 - BULLISHCLUSTEROct 22, 2026
Two insiders at Rapport Therapeutics, including the CFO and a director, made open-market purchases…
Impact 5/10 - BULLISHINSIDER-BUYOct 21, 2026
Rapport Therapeutics CFO Troy Ignelzi purchased $144K worth of RAPP shares on the open market at…
Impact 4/10 - BULLISH8-KOct 20, 2026
Rapport Therapeutics announced positive topline Phase 2 results for RAP-219 in acute bipolar…
Impact 7/10
All RAPP filing & press-release reports (22)
- CLUSTER reportOct 23, 2026
- CLUSTER reportOct 22, 2026
- INSIDER-BUY reportOct 21, 2026
- 8-K reportOct 20, 2026
- 144 reportOct 6, 2026
- CLUSTER reportOct 1, 2026
- CLUSTER reportAug 27, 2026
- 8-K reportAug 5, 2026
- 144 reportJul 3, 2026
- 144 reportJul 3, 2026
- CLUSTER reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 144 reportMay 27, 2026
- 144 reportMay 11, 2026
- 144 reportMay 8, 2026
- 144 reportMay 7, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 23, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 1, 2026
- 144 reportMar 30, 2026
- PRESS-RELEASE reportMar 10, 2026